Masako Murai

Masako Murai serves as the Vice President of Clinical Development at ADARx Pharmaceuticals Inc. since April 2025, and is the Principal at Murai Consulting, where specialization includes guiding clients through drug development processes in autoimmune and rare diseases. Previously, Masako was the Global Program Clinical Lead for SKYCLARYS at Biogen, overseeing comprehensive clinical strategies that aligned with regulatory demands. As Associate Vice President of Clinical Development at Reata Pharmaceuticals, significant achievements included the approval of SKYCLARYS for treating Friedrich ataxia. Earlier experience at The Janssen Pharmaceutical Companies of Johnson & Johnson involved leading early development plans for immunology assets, fostering collaboration across various scientific domains. Masako holds a Ph.D. in Gastroenterology and Immunology from The University of Tokyo and an M.D. from Niigata University School of Medicine.